|
مقاله
|
Abstract
|
|
|
Title:
|
Visual and anatomical outcomes of spironolactone therapy in chronic central serous chorioretinopathy
|
Author(s):
|
Khalil Ghasemi Falavarjani, Anahita Amirsardari, Abbas Habibi, Acieh Eshaghi, Kaveh Abri Aghdam
|
Presentation Type:
|
Oral
|
Subject:
|
Posterior Segment and Uveitis
|
Others:
|
|
Presenting Author:
|
|
Name:
|
Kaveh Abri aghdam
|
Affiliation :(optional)
|
Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
|
E mail:
|
kaveh_abri@yahoo.com
|
Phone:
|
0098-21-66509162
|
Mobile:
|
|
|
|
Purpose:
|
To evaluate the effects of spironolactone on chronic central serous chorioretinopathy (CSC).
|
Methods:
|
This is a prospective interventional case series on sixteen eyes of 14 patients with chronic CSC. Patients were treated with spironolactone 25 mg daily for at least 6 weeks. If there was an incomplete resolution of subretinal fluid (SRF), the treatment was continued with increasing the dosage to 25 mg twice daily. Primary outcome measures were the changes in maximum SRF height and central macular thickness (CMT) at 6 weeks and at the final follow-up visit as recorded by OCT. Secondary outcome measure was the change in BCVA.
|
Results:
|
Mean follow-up time was 6.4 ± 4.3 months. Baseline BCVA was 0.54 ± 0.44 LogMAR and improved to 0.42 ± 0.43 LogMAR at the final visit (P=0.04). Mean CMT decreased from 282.69 ± 103.23 µm at baseline to 236.75 ± 90.10 µm at final visit (p= 0.11). Mean maximum height of SRF reduced from 155.63 ± 95.27 µm at baseline to 77.19 ± 95.68 µm at the final visit (P=0.04). SRF resolved completely in 7 eyes (43.75%).
|
Conclusion:
|
In eyes with persistent SRF due to CSC, spironolactone therapy was associated with a significant reduction in maximum SRF height and BCVA improvement.
|
Attachment:
|
|
|